Cargando…
Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse(®)
Passive therapy with neutralizing human monoclonal antibodies (mAbs) could be an effective therapy against severe acute respiratory syndrome coronavirus (SARS-CoV). Utilizing the human immunoglobulin transgenic mouse, XenoMouse®, we produced fully human SARS-CoV spike (S) protein specific antibodies...
Autores principales: | Coughlin, Melissa, Lou, Gin, Martinez, Osvaldo, Masterman, Stephanie K., Olsen, Ole A., Moksa, Angelica A., Farzan, Michael, Babcook, John S., Prabhakar, Bellur S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103293/ https://www.ncbi.nlm.nih.gov/pubmed/17161858 http://dx.doi.org/10.1016/j.virol.2006.09.029 |
Ejemplares similares
-
Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms
por: Coughlin, Melissa M., et al.
Publicado: (2009) -
Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential
por: Coughlin, Melissa M., et al.
Publicado: (2011) -
Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing
por: Elshabrawy, Hatem A., et al.
Publicado: (2012) -
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
por: Xiang, Rong, et al.
Publicado: (2022) -
Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study
por: Liao, Xuejiao, et al.
Publicado: (2022)